These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

876 related articles for article (PubMed ID: 17196053)

  • 1. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
    Moreno FA; Wiegand CB; Taitano EK; Delgado PL
    J Clin Psychiatry; 2006 Nov; 67(11):1735-40. PubMed ID: 17196053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psilocybin and Obsessive Compulsive Disorder.
    Wilcox JA
    J Psychoactive Drugs; 2014; 46(5):393-5. PubMed ID: 25364991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psilocybin for the Treatment of Obsessive-Compulsive Disorders.
    Ehrmann K; Allen JJB; Moreno FA
    Curr Top Behav Neurosci; 2022; 56():247-259. PubMed ID: 34784024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study.
    Sarris J; Oliver G; Camfield DA; Dean OM; Dowling N; Smith DJ; Murphy J; Menon R; Berk M; Blair-West S; Ng CH
    CNS Drugs; 2015 Sep; 29(9):801-9. PubMed ID: 26374743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial.
    Ching THW; Grazioplene R; Bohner C; Kichuk SA; DePalmer G; D'Amico E; Eilbott J; Jankovsky A; Burke M; Hokanson J; Martins B; Witherow C; Patel P; Amoroso L; Schaer H; Pittenger C; Kelmendi B
    Front Psychiatry; 2023; 14():1178529. PubMed ID: 37181888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.
    Ching THW; Amoroso L; Bohner C; D'Amico E; Eilbott J; Entezar T; Fitzpatrick M; Fram G; Grazioplene R; Hokanson J; Kichuk SA; Martins B; Patel P; Schaer H; Shnayder S; Witherow C; Pittenger C; Kelmendi B
    Front Psychiatry; 2023; 14():1278823. PubMed ID: 38264632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.
    Koran LM; Gamel NN; Choung HW; Smith EH; Aboujaoude EN
    J Clin Psychiatry; 2005 Apr; 66(4):515-20. PubMed ID: 15816795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Placebo effect after prefrontal magnetic stimulation in the treatment of resistant obsessive-compulsive disorder: a randomized controlled trial.
    Mansur CG; Myczkowki ML; de Barros Cabral S; Sartorelli Mdo C; Bellini BB; Dias AM; Bernik MA; Marcolin MA
    Int J Neuropsychopharmacol; 2011 Nov; 14(10):1389-97. PubMed ID: 21557884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Double-Blind Randomized Placebo-Controlled Pilot Study of Azithromycin in Youth with Acute-Onset Obsessive-Compulsive Disorder.
    Murphy TK; Brennan EM; Johnco C; Parker-Athill EC; Miladinovic B; Storch EA; Lewin AB
    J Child Adolesc Psychopharmacol; 2017 Sep; 27(7):640-651. PubMed ID: 28358599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hallucinogens and obsessive-compulsive disorder.
    Perrine DM
    Am J Psychiatry; 1999 Jul; 156(7):1123. PubMed ID: 10401480
    [No Abstract]   [Full Text] [Related]  

  • 11. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
    Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ
    Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
    Feusner JD; Kerwin L; Saxena S; Bystritsky A
    Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
    Bogenschutz MP; Ross S; Bhatt S; Baron T; Forcehimes AA; Laska E; Mennenga SE; O'Donnell K; Owens LT; Podrebarac S; Rotrosen J; Tonigan JS; Worth L
    JAMA Psychiatry; 2022 Oct; 79(10):953-962. PubMed ID: 36001306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
    Storch EA; Wilhelm S; Sprich S; Henin A; Micco J; Small BJ; McGuire J; Mutch PJ; Lewin AB; Murphy TK; Geller DA
    JAMA Psychiatry; 2016 Aug; 73(8):779-88. PubMed ID: 27367832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients.
    Glick ID; Poyurovsky M; Ivanova O; Koran LM
    J Clin Psychiatry; 2008 Dec; 69(12):1856-9. PubMed ID: 19026264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients.
    Connor KM; Payne VM; Gadde KM; Zhang W; Davidson JR
    J Clin Psychiatry; 2005 Jan; 66(1):49-51. PubMed ID: 15669888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A standardized cognitive-behavioural group treatment program for obsessive compulsive disorder: preliminary outcomes].
    Bouvard M
    Encephale; 2002; 28(5 Pt 1):439-46. PubMed ID: 12386546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.
    Ghaleiha A; Entezari N; Modabbernia A; Najand B; Askari N; Tabrizi M; Ashrafi M; Hajiaghaee R; Akhondzadeh S
    J Psychiatr Res; 2013 Feb; 47(2):175-80. PubMed ID: 23063327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of therapeutic change after psychedelic treatment in OCD.
    Maloney G; Ching T; Kichuk SA; Pittenger C; Kelmendi B
    Psychiatry Res; 2024 Jun; 336():115907. PubMed ID: 38615521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study.
    Vulink NC; Denys D; Westenberg HG
    J Clin Psychiatry; 2005 Feb; 66(2):228-30. PubMed ID: 15705009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.